These findings strongly indicate that acquiring CD38 expression on tumor-reactive CD8+ T cells leads to impaired anti-tumor potential and responsiveness to anti-PD1 therapy due to the loss of TCF1 expression. This evidence concerns the gene PDCD1 and neoplasm.